Literature DB >> 11848467

Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer.

Q Liao1, H Friess, J Kleeff, M W Büchler.   

Abstract

BACKGROUND: Pancreatic cancer is one of the most aggressive cancers, in part due to its insensitivity to most treatment modalities. This resistance towards cytotoxic therapy is thought to be caused--at least in part--by a general resistance of pancreatic cancer cells towards apoptosis. TRAIL-R3 and TRAIL-R4, which belong to the TRAIL receptor family, can inhibit TRAIL-induced apoptosis. PATIENTS AND METHODS: Seven normal pancreatic tissues and 7 pancreatic cancer tissues were analyzed using Northern blotting, Western blotting and immunohistochemistry.
RESULTS: TRAIL-R3 mRNA and protein expression were generally weak in pancreatic cancers and normal pancreatic tissues. In contrast, TRAIL-R4 mRNA and protein were expressed at moderate to high levels in human pancreatic cancer tissues, but demonstrated weak to negative expression in the normal pancreas.
CONCLUSION: TRAIL-R4 but not TRAIL-R3 levels were significantly different in pancreatic cancer in comparison to the normal pancreas. These findings give new insight into the resistance mechanisms of pancreatic cancer towards TRAIL-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11848467

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Localization of TRAIL/TRAILR in fetal pancreas.

Authors:  Li-Hua Chen; Xue-Song Liu; Wen-Yong Wang; Wei-Ning Han; Bo-Rong Pan; Bo-Quan Jin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

2.  Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Zhen Fan; Douglas B Evans; Paul J Chiao
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

Review 3.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

Authors:  Andrew Thorburn; Kian Behbakht; Heide Ford
Journal:  Drug Resist Updat       Date:  2008-04-18       Impact factor: 18.500

4.  Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.

Authors:  Tom M Ganten; Jaromir Sykora; Ronald Koschny; Emanuela Batke; Sebastian Aulmann; Ulrich Mansmann; Wolfgang Stremmel; Hans-Peter Sinn; Henning Walczak
Journal:  J Mol Med (Berl)       Date:  2009-08-13       Impact factor: 4.599

5.  Targeting apoptosis signaling in pancreatic cancer.

Authors:  Simone Fulda
Journal:  Cancers (Basel)       Date:  2011-01-11       Impact factor: 6.639

Review 6.  Apoptosis pathways and their therapeutic exploitation in pancreatic cancer.

Authors:  Simone Fulda
Journal:  J Cell Mol Med       Date:  2009-03-27       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.